NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column acquired 53,172 shares of NGM Biopharmaceuticals stock in a transaction on Friday, October 11th. The stock was acquired at an average price of $10.38 per share, with a total value of $551,925.36. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of NYSE:NGM opened at $10.27 on Tuesday. NGM Biopharmaceuticals has a 1 year low of $8.81 and a 1 year high of $19.27. The company has a fifty day simple moving average of $14.94.
NGM Biopharmaceuticals (NYSE:NGM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.71. The firm had revenue of $25.34 million for the quarter, compared to the consensus estimate of $19.00 million.
Several hedge funds have recently bought and sold shares of the company. Royal Bank of Canada bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $17,691,000. Svennilson Peter bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $229,762,000. Victory Capital Management Inc. bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $1,870,000. Citadel Advisors LLC bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $289,000. Finally, Pentwater Capital Management LP bought a new position in shares of NGM Biopharmaceuticals during the 2nd quarter worth $309,000.
About NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.